

## NEWS &amp; VIEWS

## BIOMECHANICS

# Barefoot running strikes back

William L. Jungers

**Detailed analyses of foot kinematics and kinetics in barefoot and shod runners offer a refined understanding of bipedalism in human evolution. This research will also prompt fresh studies of running injuries.**

A commitment to walking and running on two legs distinguishes humans from apes, and has long been the defining adaptation of the hominins — the lineages that include both humans and our extinct relatives. This form of locomotion (bipedalism) has been around for millions of years, and we have been unshod for more than 99% of that time<sup>1</sup>. The uniquely specialized anatomy of the human foot<sup>2</sup> is thus a product of barefoot bipedalism, which is still the norm in parts of the world. Lieberman and colleagues' biomechanical research on the subject (page 531 of this issue)<sup>3</sup>, therefore has implications for interpreting human evolution. It also has some potentially useful and thought-provoking implications for sports medicine and running-shoe design. (Full disclosure: I don't run any more, either barefoot or in shoes.)

Most shod runners today make initial contact with the ground heel-first (rear-foot striking, or RFS). Experienced barefoot runners, like the ones observed for this study<sup>3</sup>, land on the ground in many ways depending on the conditions — sometimes RFS, but more often avoiding landing heel-first because it hurts owing to repetitive, high-impact forces (or transients). A more anterior landing on a flat foot (mid-foot striking, or MFS), or on the lateral ball of the foot (fore-foot striking, or FFS), has predictable, and some would say desirable, consequences for pedal biomechanics. In FFS and some MFS, the foot's centre of pressure necessarily starts more anterior at contact and then moves backward briefly before moving forward again for toeing-off. (Sprinters, whether shod or not, also run on their forefeet, but for different mechanical reasons.) Among other differences, FFS barefoot runners tend to take shorter strides and to run with greater vertical leg and ankle compliance (the lowering of the body's centre of mass relative to the force of the impact). This serves to blunt the transient force and results in a less jarring, 'smoother ride'. The elevated and cushioned heel of most modern running shoes is designed for comfort, stability and to attenuate the transient forces of heel-strike in RFS running that may be linked to some orthopaedic injuries.

Lieberman and colleagues' multifaceted



**Figure 1 | Different footfalls.** These photos are of two Kalenjin runners from Kenya, a barefoot 12-year-old girl (left) and a boy of the same age in running shoes. Note the differences in foot angulation as the girl prepares for a forefoot touchdown and the boy prepares to land heel first. (Photos courtesy of D. E. Lieberman.)

study<sup>3</sup> corroborates and extends what is known about the basic mechanics of barefoot running, as they develop a collisional model of the foot and leg as an 'L-shaped double pendulum' with the same dimensions as a typical shank and foot. They then calculate how much energy such a pendulum exchanges with the ground when it collides at different points and with a stiff or compliant ankle. They also broaden the comparative human database by studying the phenomenon not only in long-term, habitual barefoot runners in a laboratory setting but also on the runners' home turf in Africa (Fig. 1). They find that FFS (and some MFS) reduces the effective mass of the foot and converts some translational energy into rotational energy; the calf muscles control heel drop, and the FFS runner can take fuller advantage of elastic energy storage in both the Achilles tendon and the longitudinal arch of the foot. FFS and MFS runners therefore require more calf- and foot-muscle strength, but avoid uncomfortable and potentially injurious impact transients even when barefoot on very hard surfaces.

The findings of this study complement and strengthen Bramble and Lieberman's influential endurance-running hypothesis (ERH)

for the transformation of the human body plan with the emergence of the genus *Homo*<sup>4</sup>. The much earlier australopithecine version of bipedalism (as seen in 'Lucy', *Australopithecus afarensis*) was long-lived and a great success by any standard. However, this skeletal design received a major make-over near the Pliocene/Pleistocene boundary about 2 million years ago. Longer hindlimbs and shorter toes are part of this new package, and if the ERH is correct, the evolution of these features along with a fully arched foot is probably linked directly to barefoot running as an integral part of an adaptive strategy for pursuit hunting<sup>5,6</sup>. The australopithecine bare foot was well-suited for heel-to-toe walking and perhaps for short, rapid bursts of sprinting<sup>7</sup>. But Lucy was not a marathoner.

The blogosphere and popular magazines are full of debate about barefoot running, with testimonials to it as a more 'natural' and less injury-prone style, and often with a nod to the ERH and an appeal to the evolutionary primacy of the unshod foot. Sometimes barefoot advocacy can take on evangelical overtones<sup>8</sup>. But it is also clear that running-shoe companies and other footwear designers are paying attention,

and they should take note of this new study<sup>3</sup>. Barefoot-like designs for footwear are currently the rage, even if they still constitute only a small slice of the enormous running-shoe industry. Many shod runners never develop injuries, but the available data indicate that at least some (19–79%) do<sup>9</sup>. Although there is no hard proof that running in shoes, especially hi-tech or PCECH (pronation control, elevated cushioned heel) versions, causes injuries, in my view there is no compelling evidence that it prevents them either<sup>10,11</sup>. However, there are data that implicate shoes more generally as a plausible source of some types of chronic foot problems<sup>12,13</sup>.

More studies like that of Lieberman *et al.*<sup>3</sup> are required to provide data instead of opinion, and testable models and scientific explanation instead of anecdotes. It is also apparent that a carefully designed biomedical study with an evidence-based approach is badly needed to assess the competing claims as to what, if anything, is the best cover for a runner's foot. It will

be interesting to see where the next foot falls, and how it is wrapped.

William L. Jungers is in the Department of Anatomical Sciences, Stony Brook University Medical Center, Stony Brook, New York 11794-8081, USA.  
e-mail: william.jungers@stonybrook.edu

- Trinkaus, E. *J. Arch. Sci.* **32**, 1515–1526 (2005).
- Kleinerman, L. & Wood, B. A. *The Human Foot: A Companion to Clinical Studies* (Springer, 2006).
- Lieberman, D. E. *Nature* **463**, 531–535 (2010).
- Bramble, D. M. & Lieberman, D. E. *Nature* **432**, 345–352 (2004).
- Rolian, C. *et al.* *J. Exp. Biol.* **212**, 713–721 (2009).
- Lieberman, D. E., Bramble, D. M., Raichlen, D. A. & Shea, J. J. In *The First Humans* (eds Grine, F. E., Fleagle, J. G. & Leakey, R. E.) 77–98 (Springer, 2009).
- Lee, S. S. M. & Piazza, S. J. *J. Exp. Biol.* **212**, 3700–3707 (2009).
- McDougall, C. *Born to Run: A Hidden Tribe, Superathletes, and the Greatest Race the World Has Never Seen* (Knopf, 2009).
- van Gent, R. N. *et al.* *Br. J. Sports Med.* **41**, 469–480 (2007).
- Richards, C. E., Magin, P. J. & Callister, R. *Br. J. Sports Med.* **43**, 159–162 (2009).
- Kerrigan, D. C. *et al.* *PM&R* **1**, 1058–1063 (2009).
- Rao, U. B. & Joseph, B. *J. Bone Joint Surg.* **74B**, 525–527 (1992).
- Zipfel, B. & Berger, L. R. *The Foot* **17**, 205–213 (2007).

because they lack the typical T-cell surface receptor and do not respond to antigens. They do, however, respond to IL-2, in line with their expression of the common  $\gamma$ -chain receptor, which functions as the signalling component of the IL-2 receptor.

Moro and colleagues<sup>4</sup> name these cells 'natural helper cells' and, on the basis of similar activation properties<sup>5</sup>, draw analogies with the natural killer cell (NK cell) — a type of lymphocyte that forms part of the innate immune defence against viruses and tumour cells, and that responds to cytokine stimulation and/or cell-surface components rather than specific antigens. However, natural helper cells lack NK-cell-lineage markers and, unlike NK cells, bear receptors commonly found on progenitor (rather than differentiated) cells, such as the IL-7 receptor and stem-cell-factor receptor (c-Kit). In view of these characteristics, it might be more accurate to call these cells 'natural  $T_{H}2$  cells'.

The abundance of these cells is limited by the small size and number of FALCs. Nevertheless, their strategic location and the particular cytokines that they secrete endow them with considerable functional impact. Indeed, Moro *et al.*<sup>4</sup> show that, in mice, these cells help to combat infection with the hookworm-like helminth parasite *Nippostrongylus brasiliensis* by inducing proliferation of B cells in Peyer's patches (lymph-node-like structures in the gut wall) and mucus formation, which helps to expel worms from the gut (Fig. 1).

The natural helper cells produce IL-5 and IL-13 in response to IL-25 (and IL-2), and also in response to IL-33, an atypical cytokine that activates the cell through the ST2 receptor<sup>6</sup> (Fig. 1). IL-33 is secreted largely by non-lymphoid cells such as endothelial cells that line blood vessels, epithelial cells, fibroblasts and,

## IMMUNOLOGY

# The expanding $T_{H}2$ universe


Warren Strober

**$T_{H}2$  growth factors, which are involved in allergy and in defence against parasites, are produced by many different cell types, including a newly identified population found in fat-associated lymph clusters in the abdomen.**

It is almost 25 years since the publication of Mosmann and Coffman's seminal work<sup>1</sup> that defined two main subtypes of helper T lymphocyte:  $T_{H}1$  cells and  $T_{H}2$  cells. The  $T_{H}2$  cells of this dichotomy were shown to produce a collection of growth factors (cytokines) and cell-attractant molecules (chemokines) that are involved in mediating allergic responses and host defence against parasitic infection. But the properties of the original  $T_{H}2$  T lymphocyte are now known to be shared by several different cell types. For instance, a recently reported subpopulation of T cells,  $T_{H}9$  T cells<sup>2</sup>, produce IL-9 and IL-10 —  $T_{H}2$ -type cytokines that exacerbate allergic inflammation. In addition, cells that produce IL-25 (macrophages, epithelial cells and mast cells) induce others to secrete the  $T_{H}2$ -type cytokines IL-5 and IL-13, and chemoattractants of eosinophils — inflammatory cells that contribute to allergic diseases and  $T_{H}2$ -type host defences<sup>3</sup>. Thus, we currently think of ' $T_{H}2$ ' not so much in the context of a cell, but rather as a function or, in business parlance, a 'franchise'. On page 540 of this issue, another cell contributing to the  $T_{H}2$  franchise is reported by Moro and colleagues<sup>4</sup>.

The authors detected the new cell population in previously overlooked fat-associated lymphoid clusters (FALCs), which are scattered along the blood vessels in the peritoneal

mesentery (a vascular membrane that surrounds part of the intestine in the abdomen). The researchers show that these cells do produce  $T_{H}2$  cytokines, but that they are not T cells



**Figure 1 | Newly discovered 'natural helper cells'.** **a**, Moro and colleagues<sup>4</sup> identify a population of cells producing  $T_{H}2$ -type cytokines in tiny accumulations of lymphoid cells, termed fat-associated lymphoid clusters (FALCs), in the mesentery. **b**, These cells can be stimulated by the cytokines IL-25 and IL-2 and by the atypical cytokine IL-33, which signals the cell through the ST2 receptor. Natural helper cells produce  $T_{H}2$  cytokines, including IL-13, inducing proliferation of B lymphocytes in Peyer's patches and the production of mucus, factors that counter infection with helminth worms. The cytokines produced by natural helper cells also support B1-lymphocyte maintenance and production of antibodies by B cells in the spleen.